Column Group’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-156,270
| Closed | -$5.29M | – | 4 |
|
|
2025
Q4 | $5.29M | Sell |
156,270
-9,805
| -6% | -$304K | 6.39% | 4 |
|
|
2025
Q3 | $4.28M | Sell |
166,075
-1,162,538
| -88% | -$15.2M | 5.29% | 4 |
|
|
2025
Q2 | $10.6M | Buy |
1,328,613
+1,162,536
| +700% | +$8.87M | 16.17% | 3 |
|
|
2025
Q1 | $1.62M | Hold |
166,077
| – | – | 3.67% | 4 |
|
|
2024
Q4 | $2.1M | Sell |
166,077
-169,001
| -50% | -$2.15M | 3.77% | 4 |
|
|
2024
Q3 | $5.39M | Hold |
335,078
| – | – | 7.74% | 4 |
|
|
2024
Q2 | $8.18M | Hold |
335,078
| – | – | 11.47% | 4 |
|
|
2024
Q1 | $24.1M | Hold |
335,078
| – | – | 14.99% | 4 |
|
|
2023
Q4 | $66.6M | Hold |
335,078
| – | – | 44% | 1 |
|
|
2023
Q3 | $44.6M | Hold |
335,078
| – | – | 29.58% | 1 |
|
|
2023
Q2 | $50.1M | Hold |
335,078
| – | – | 19.45% | 3 |
|
|
2023
Q1 | $49.2M | Hold |
335,078
| – | – | 17.79% | 3 |
|
|
2022
Q4 | $53.1M | Buy |
335,078
+21
| +0% | +$3.36K | 17.67% | 3 |
|
|
2022
Q3 | $64.5M | Hold |
335,057
| – | – | 14.27% | 3 |
|
|
2022
Q2 | $48.9M | Buy |
335,057
+159,806
| +91% | +$21.3M | 10.41% | 4 |
|
|
2022
Q1 | $30.8M | Hold |
175,251
| – | – | 5.72% | 4 |
|
|
2021
Q4 | $51.5M | Hold |
175,251
| – | – | 7% | 6 |
|
|
2021
Q3 | $43.5M | Sell |
175,251
-310,459
| -64% | -$82.1M | 4.95% | 7 |
|
|
2021
Q2 | $124M | Hold |
485,710
| – | – | 17.48% | 2 |
|
|
2021
Q1 | $86.3M | Hold |
485,710
| – | – | 8.26% | 5 |
|
|
2020
Q4 | $76.7M | Buy |
+485,710
| New | +$106M | 6.96% | 5 |
|
Column Group's RAPT Position: Q1 2026 in Review
Column Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 156,270 shares — an estimated $5.29M sold.
Column Group first reported a position in RAPT in Q4 2020 and held it in 21 quarters. The position peaked at $124M in Q2 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Column Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Column Group sold 156,270 RAPT Therapeutics shares in Q1 2026, an estimated $5.29M.
- Column Group first reported a position in RAPT Therapeutics in Q4 2020 and held it in 21 quarters.
- Column Group's RAPT Therapeutics position peaked at $124M in Q2 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Column Group's 13F filing for Q1 2026, filed 18 May 2026.